Phase 2 Muscular Dystrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with a condition called Myotonic Dystrophy Type 1 (DM1), confirmed by a genetic blood test showing more than 150 repeats of a specific gene change
- You are able to walk on your own and can complete a 10-meter walk or run test without using aids like canes, walkers, or leg braces — though ankle-foot braces (worn around the ankle and foot) are allowed
- You experience muscle stiffness (called myotonia) in your grip that lasts for more than 3 seconds, as confirmed by a specialist reviewer
Who may not be able to join:
- People who were born with DM1 (known as congenital DM1, meaning symptoms were present from birth)
- People who have significant weakness in the muscle at the front of the lower leg (shin area), or too much muscle loss there to safely perform a small muscle tissue sample (biopsy)
- People who have taken mexiletine or any other medication used to treat muscle stiffness (myotonia) within roughly the past 3 weeks or longer, depending on the specific medication (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +34676229821
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.